Ovarian Cancer Trial, Recruiting (NCT06295965)

Ovarian Cancer Trial, Recruiting NCT06295965 Sponsor: University of Washington Condition: Ovarian Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06295965 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Ovarian Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with ovarian cancer, peritoneal cancer, or fallopian tube cancer, are expected to live more than 6 months, and have completed or are planning to complete at least 5 rounds of platinum-based chemotherapy.
You have been diagnosed with any solid tumor (a type of cancer that forms a lump or mass) and have taken a type of cancer drug called a PARP inhibitor for at least 4 months.
You have been diagnosed with any solid tumor and also have a blood disorder, which may include conditions such as clonal hematopoiesis of indeterminate potential, cytopenia of unknown significance, or a treatment-related blood or bone marrow condition (confirm with trial site if unsure whether your specific condition qualifies).

Who may not be able to join:

You are not expected to live more than 6 months.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 26 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Elizabeth Swisher, Fred Hutch/University of Washington Cancer Consortium

Phone: 206-616-8927

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06295965

Sponsor: University of Washington

Phase: Not Applicable

Status: Recruiting

Condition: Ovarian Cancer

Trial contact: 206-616-8927

More information: https://clinicaltrials.gov/study/NCT06295965

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with ovarian cancer, peritoneal cancer, or fallopian tube cancer, are expected to live more than 6 months, and have completed or are planning to complete at least 5 rounds of platinum-based chemotherapy.
You have been diagnosed with any solid tumor (a type of cancer that forms a lump or mass) and have taken a type of cancer drug called a PARP inhibitor for at least 4 months.
You have been diagnosed with any solid tumor and also have a blood disorder, which may include conditions such as clonal hematopoiesis of indeterminate potential, cytopenia of unknown significance, or a treatment-related blood or bone marrow condition (confirm with trial site if unsure whether your specific condition qualifies).

Who may not be able to join:

You are not expected to live more than 6 months.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 26 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University of Washington

Registry

ClinicalTrials.gov

Start date

2 January 2024

Est. completion

31 December 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Determine the correlation between baseline TP53m VAF in blood with CH expansion in OC patients; Identify risk of TMN for OC survivors with and without TP53m CH treated with platinum chemotherapy and PARP inhibitors; Define the trajectories of clonal evolution and mechanisms of transformation from non-cancerous TP53m to TMN

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov